The America Pouchitis Treatment Market is expected to grow at a CAGR of 8.34% during the forecast period 2017-2023.
Pouchitis is one of the most common complications of ileal pouch-anal anastomosis (IPAA) surgery and has a significant adverse impact on the quality of life. Pouchitis is an inflammation of the surgically constructed pouch. Various therapies are recommended for the treatment of pouchitis such as antibiotics, budesonide enemas, probiotics, probiotics, butyrate suppositories, bismuth enemas, and others.
Increasing need for ileal pouch-anal anastomosis procedure, long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs), rising prevalence of ulcerative colitis (UC), and increasing geriatric population are the key factors driving the pouchitis treatment market.
However, the side effects of the available treatment options and stringent FDA regulations may hinder the growth of the market to an extent. Till now not even a single drug is approved by the FDA for the treatment of pouchitis. However, few are in clinical trials waiting for approval such as Alicaforsen by Atlantic Healthcare plc.
Key Players in the Americas Pouchitis Treatment Market:
- Allergan Plc
- Takeda Pharmaceutical Company Limited
- Alfa sigma
- Atlantic Healthcare
- Tillotts Pharma AG
- Novartis AG
- Teva Pharmaceutical Industries Ltd
- Braun Medical Inc.
- Valeant Pharmaceuticals
- The America pouchitis treatment market is segmented on the basis of treatment and end user.
- On the basis of the treatment, the market is segmented into antibiotics, probiotics, and others. The antibiotic segment is further sub-segmented into ciprofloxacin, metronidazole, rifaximin, and others.
- On the basis of the end -users, the market is segmented into hospitals & clinics, research institutes, and others.
On the basis of region, the America pouchitis treatment market is segmented into North America, and South America. North America accounts for a major share owing to the rising cases of pouchitis and high healthcare expenditure. People in this region are more inclined towards quality healthcare that leads to increase in the healthcare spending. Due to rising prevalence of pouchitis, various companies, private organizations, and government associations are also actively participating to improve the treatment options.
The Americas pouchitis market is driven by ongoing extensive research in the inflammatory bowel disease (IBD). The American Gastroenterological Association (AGA) has introduced several new research grants to support investigators studying inflammatory bowel disease (IBD) such as Takeda Pharmaceuticals research scholar awards in IBD, and Pfizer pilot research award in IBD.
Around 30% of patients with ulcerative colitis (UC) undergo colectomy with ileal pouch-anal anastomosis (IPAA) surgery, and up to 50% of patients develop at least one episode of pouchitis. So, rising prevalence of ulcerative colitis is boosting the America pouchitis treatment market. According to the Centers for Disease Control and Prevention, in 2015, around 1.3% of the U.S. adults were diagnosed with inflammatory bowel disease (IBD). The prevalence of ulcerative colitis is reported to be 37 to 246 cases per 100,000 individuals whereas, the incidence rate is found to be 2.2 to 14.3 cases per 100,000 people.